BiotechTube

CABA-201

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing Multiple Sclerosis (RMS)

Conditions

Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis

Trial Timeline

Jun 1, 2026 → Oct 1, 2029

NCT ID
NCT07006805

About CABA-201

CABA-201 is a phase 1/2 stage product being developed by Cabaletta Bio for Relapsing Multiple Sclerosis (RMS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07006805. Target conditions include Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing Multiple Sclerosis (RMS) were approved

Approved (20) Terminated (2) Active (0)
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved
✅Interferon beta-1aMerckApproved
✅Cladribine 10 mg oral tabletMerckApproved
✅Rebif® (clone 484-39)MerckApproved
✅RebifMerckApproved
✅Fingolimod 0.5 mgNovartisApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07006805Phase 1/2Recruiting
NCT06359041Phase 1/2Active
NCT06328777Phase 1/2Recruiting

Competing Products

20 competing products in Relapsing Multiple Sclerosis (RMS)

See all competitors
ProductCompanyStageHype Score
Placebo + PirtobrutinibEli LillyPhase 2
27
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
dirucotide + placeboEli LillyPhase 2/3
38
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRNMerckPhase 3
40
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Teriflunomide + EvobrutinibMerckPhase 3
32
Cladribine + Placebo + Microgynon®MerckPhase 1
29